Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes

•Teri-LIFE is the first observational study carried out in the Nordic region to assess quality-of-life (QoL), treatment satisfaction, efficacy, safety, and health economic outcomes in persons with relapsing MS treated with teriflunomide in routine clinical practice.•200 patients were enrolled and followed for up to 24 months.•QoL remained stable over the course of the study, while treatment satisfaction scores highlighted the convenience and reduced side effects of this once-daily oral medication.•Efficacy and safety outcomes were consistent with previous clinical trials and real-world studies.